Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains

Infection and Immunity

Volumn 71, Issue 5, 2003, Pages 2868-2875

  Kozel, Thomas R ^a   Levitz, Stuart M ^b   Dromer, Françoise ^c   Gates, Marcellene A ^a   Thorkildson, Peter ^a   Janbon, Guilhem ^c  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY; POLYSACCHARIDE; XYLOSE;

ACETYLATION; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CELL WALL; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CRYPTOCOCCUS NEOFORMANS; FUNGAL CELL; FUNGAL GENE; FUNGAL STRAIN; FUNGUS MUTANT; GENE MUTATION; MOUSE; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SEROTYPE; VIRULENCE; YEAST CELL;

ACETYLATION; ANTIBODIES, MONOCLONAL; COMPLEMENT C3; COMPLEMENT FACTOR H; CRYPTOCOCCUS NEOFORMANS; HUMANS; MUTATION; NEUTROPHILS; PHAGOCYTOSIS; POLYSACCHARIDES; XYLOSE;

EID: 0242668758     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.5.2868-2875.2003     Document Type: Article

References (51)

1. Bar-Peled, M., C. L. Griffith, and T. L. Doering. 2001. Functional cloning and characterization of a UDP-glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis. Proc. Natl. Acad. Sci. USA 98:12003-12008.
2. Belay, T., and R. Cherniak. 1995. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect. Immun. 63:1810-1819.
3. Belay, T., R. Cherniak, T. R. Kozel, and A. Casadevall. 1997. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect. Immun. 65:718-728.
4. Bhattacharjee, A. K., J. E. Bennett, and C. P. J. Glaudemans. 1984. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 6:619-624.
5. Bulmer, G. S., and M. D. Sans. 1968. Cryptococcus neoformans. III. Inhibition of phagocytosis. J. Bacteriol. 95:5-8.
6. Bulmer, G. S., M. D. Sans, and C. M. Gunn. 1967. Cryptococcus neoformans. I. Nonencapsulated mutants. J. Bacteriol. 94:1475-1479.
7. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect. Immun. 59:59-64.
8. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans. Mol. Immunol. 17:1025-1032.
9. Cherniak, R., H. Valafar, L. C. Morris, and F. Valafar. 1998. Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146-159.
10. Delfino, D., L. Cianci, E. Lupis, A. Celeste, M. L. Petrelli, F. Curro, V. Cusumano, and G. Teti. 1997. Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect. Immun. 65:2454-2456.
11. Denning, D. W., R. W. Armstrong, B. H. Lewis, and D. A. Stevens. 1991. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am. J. Med. 91:267-272.
12. Dong, Z. M., and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Investig. 97:689-698.
13. Dong, Z. M., and J. W. Murphy. 1997. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect. Immun. 65:557-563.
14. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
15. Friedman, J. J. 1955. Organ plasma volume of normal unanesthetized mice. Proc. Soc. Exp. Biol. Med. 88:323-325.
16. Fromtling, R. A., H. J. Shadomy, and E. S. Jacobson. 1982. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 79:23-29.
17. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448-3453.
18. Granger, D. L., J. R. Perfect, and D. T. Durack. 1985. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Investig. 76:508-516.
19. Grinsell, M., L. C. Weinhold, J. E. Cutler, Y. Han, and T. R. Kozel. 2001. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184:479-487.
20. Hirano, A., H. M. Zimmerman, and S. Levine. 1964. The fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage. Am. J. Pathol. 45:1-19.
21. Hirano, A., H. M. Zimmerman, and S. Levine. 1964. The fine structure of cerebral fluid accumulation. IV. On the nature and origin of extracellular fluids following cryptococcal polysaccharide implantation. Am. J. Pathol. 45:195-207.
22. Horstmann, R. D., M. K. Pangburn, and H. J. Muller-Eberhard. 1985. Species specificity of recognition by the alternative pathway of complement. J. Immunol. 134:1101-1104.
23. Horstmann, R. D., H. J. Sievertsen, J. Knobloch, and V. A. Fischetti. 1988. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl. Acad. Sci. USA 85:1657-1661.
24. Janbon, G., U. Himmelreich, F. Moyrand, L. Improvisi, and F. Dromer. 2001. Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol. Microbiol. 42:453-467.
25. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
26. Kozel, T. R., W. F. Gulley, and J. Cazin, Jr. 1977. Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18:701-707.
27. Kozel, T. R., and C. A. Hermerath. 1988. Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column. J. Immunol. Methods 107:53-58.
28. Kozel, T. R., and R. P. Mastroianni. 1976. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14:62-67.
29. Kozel, T. R., and G. S. T. Pfrommer. 1986. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52:1-5.
30. Kozel, T. R., M. A. Wilson, and J. W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59:3101-3110.
31. Kozel, T. R., M. A. Wilson, G. S. T. Pfrommer, and A. M. Schlageter. 1989. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57:1922-1927.
32. Kwon-Chung, K. J., and J. C. Rhodes. 1986. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect. Immun. 51:218-223.
33. MacGill, T. C., R. S. MacGill, A. Casadevall, and T. R. Kozel. 2000. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J. Immunol. 164:4835-4842.
34. Mambula, S. S., E. R. Simons, R. Hastey, M. E. Selsted, and S. M. Levitz. 2000. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect. Immun. 68:6257-6264.
35. Moyrand, F., B. Klaproth, U. Himmelreich, F. Dromer, and G. Janbon. 2002. Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol. Microbiol. 45:837-849.
36. Murphy, J. W., and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896-901.
37. Netski, D., and T. R. Kozel. 2002. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun. 70:2812-2819.
38. Pettoello-Mantovani, M., A. Casadevall, T. R. Kollmann, A. Rubinstein, and H. Goldstein. 1992. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339:21-23.
39. Pettoello-Mantovani, M., A. Casadevall, P. Smarnworawong, and H. Goldstein. 1994. Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res. Hum. Retrovir. 10:1079-1087.
40. Pfrommer, G. S. T., S. M. Dickens, M. A. Wilson, B. J. Young, and T. R. Kozel. 1993. Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule. Infect. Immun. 61:4360-4366.
41. Retini, C., A. Vecchiarelli, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64:2897-2903.
42. Sahu, A., T. R. Kozel, and M. K. Pangburn. 1994. Specificity of the thioestercontaining reactive site of human C3 and its significance to complement activation. Biochem. J. 302:429-436.
43. Segal, D. M. 1995. Antibody detection and preparation, p. 2.0.1-2.13.16. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
44. Shoham, S., C. Huang, J.-M. Chen, D. T. Golenbock, and S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166:4620-4626.
45. Spiropulu, C., R. A. Eppard, E. Otteson, and T. R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect. Immun. 57:3240-3242.
46. Taborda, C. P., and A. Casadevall. 2002. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16:791-802.
47. Turner, S. H., and R. Cherniak. 1991. Multiplicity in the structure of the glucuronoxylomannan of Cryptococcus neoformans, p. 123-142. In J. P. Latgé and D. Boucias (ed.), Fungal cell wall and immune response. Springer-Verlag, Berlin, Germany.
48. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect. Immun. 63:2919-2923.
49. Wickes, B. L., and J. C. Edman. 1995. The Cryptococcus neoformans GAL7 gene and its use as an inducible promoter. Mol. Microbiol. 16:1099-1109.
50. Wilson, D. E., J. E. Bennett, and J. W. Bailey. 1968. Serologic grouping of Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. 127:820-823.
51. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype and structural modification on the kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966-2972.